Use of COVID-19 Vaccines in the United States

Interim Clinical Considerations

Healthcare providers who administer the Moderna COVID-19 Vaccine (2023-2024 Formula) to individuals ages 6 months through 11 years should ensure the correct volume of the vaccine (0.25 mL) is withdrawn from the vial and administered to the recipient. Discard vial and excess volume after extracting a single dose.

For additional information, see FDA Announcement and Moderna COVID-19 Vaccine (2023-2024 Formula) Healthcare Provider Fact Sheet (

Summary of recent changes (last updated April 4, 2024):
  • New guidance on COVID-19 vaccination and pemivibart (Pemgarda™), a monoclonal antibody authorized for COVID-19 pre-exposure prophylaxis in people who are moderately or severely immunocompromised and meet the FDA-authorized conditions for use.